Britain and America have announced a major trade agreement that will keep zero levies on British pharmaceutical exports being sold in the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to raise funding on pharmaceuticals through the public health system. This commitment ensures that tariffs on these vital products will be held at zero for a timeframe of the next three years.
This agreement is in response to recent threats to significantly raise tariffs on patented drug imports, with increases mentioned reaching 100%.
"This agreement with the UK bolsters the worldwide climate for new treatments and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement declared.
Economic Impact
Medicines are one of the the United Kingdom's most significant exports to the America, which is easily the biggest market for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to September, the UK shipped drugs worth over eleven billion pounds to the US. This value accounted for a significant portion of all goods exports in that span.
"This agreement protects jobs, boosts investment and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official remarked.
Detailed British Pledges
The agreement includes several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to control costs will be limited at fifteen percent. Last year, repayments topped 20%.
Industry Background
The pact takes place against a ongoing dispute between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
These tensions were intensified by claims that American consumers were charged a premium for the equivalent treatments than people in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had decreased as a proportion of its resources over the last ten years.
